The Nanolek biopharmaceutical company received a registration certificate from the Ministry of Health of Belarus for an inactivated polio prevention vaccine Polymilex. This is stated in the company’s message. The corresponding certificate was issued on December 15, 2020 for five years.
“There is currently a shortage of inactivated polio vaccines on the international market. Nanolek, as a socially responsible company, supports the WHO global polio eradication programme with a planned shift to inactivated vaccines instead of live vaccines. Belarus is also concerned about this problem. To immunize a relevant cohort of children, according to experts in Belarus, about 300 thousand doses of polio vaccine will be required, “said the President of the company Vladimir Khristenko.
The vaccine direction is more than 40% of the company’s total portfolio. Nanolek, together with the Dutch company Bilthoven Biologicals, in 2012 launched a project for the phased transfer of technology for the production of inactivated polio prevention vaccine Polymilex, in 2017 production began at a full cycle (all stages, including production quality control) at the Nanolek production facilities in Russia in the Kirov region. Today, production volumes completely cover the current needs of the Russian market: from 2017 to 2020. 10 million doses of vaccine were delivered for the National Calendar of Preventive Vaccinations.